# Expansion of SARS-CoV-2 Testing Supplement, Chicago Clinical Trials Unit

> **NIH NIH UM1** · NORTHWESTERN UNIVERSITY · 2020 · $814,136

## Abstract

Parent Award Project Summary
The Chicago Clinical Trials Unit (CCTU) is a consortium of five Clinical Research Sites (CRSs) which will
address three priority clinical research areas of the NIAID: 1) adult HIV therapeutic strategies including HIV
cure, noninfectious comorbidities, and infectious co-morbidities of hepatitis and tuberculosis; 2) vaccines to
prevent HIV; and 3) integrated HIV prevention strategies. The CCTU consists of five highly experienced and
scientifically productive CRSs that are uniquely positioned to develop, implement and adapt the clinical
research priorities of the NIAID clinical research priority areas. The CCTU has a proven track record and will
continue its productivity through active engagement with a diverse host of at risk and HIV-impacted
communities, participation in high impact, ground-breaking clinical research studies, efficient management of
resources and critical performance oversight of the clinical activities, laboratories, and pharmacies. The CCTU
includes CRSs and personnel that have long term and productive involvement with three of the research
networks; the fourth-antibacterial resistance-being a new network in this consortium. The CRSs and their
network affiliations include: Northwestern University (adult HIV therapeutic strategies); University of Illinois
Chicago (vaccines to prevent HIV, integrated HIV prevention), Rush University (adult HIV therapeutic
strategies), University of Chicago (integrated HIV prevention strategies) and Trinity Health & Wellness Center
(adult HIV therapeutic strategies). Four of the CRSs are located in Chicago, an ethnically and racially diverse
urban area of 9.5 million persons that is the third largest metropolitan region in the United States and one of
the major urban HIV epicenters. The aims of this proposal are: development, implementation and adaptation of
the clinical research program of the 1) Adult HIV Therapeutics Strategy Network, 2) the Vaccines to Prevent
HIV Network, 3) the Integrated HIV Prevention Strategies Network, and 4) Bidirectional engagement of the
relevant and at risk HIV-infected/impacted communities with the CCTU clinical researchers. The CCTU is well
positioned to reach diverse populations and contribute significantly to the NIAID research agenda.

## Key facts

- **NIH application ID:** 10166472
- **Project number:** 3UM1AI069471-14S1
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** Babafemi O Taiwo
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $814,136
- **Award type:** 3
- **Project period:** 2020-06-17 → 2022-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10166472

## Citation

> US National Institutes of Health, RePORTER application 10166472, Expansion of SARS-CoV-2 Testing Supplement, Chicago Clinical Trials Unit (3UM1AI069471-14S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10166472. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*